ZTlido ® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company. Gloperba ® is the subject of an exclusive, transferable license to use the ...

TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies ...

ZTlido ® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company. Gloperba ® is the subject of an exclusive, transferable license to use the ...

Although psoriasis is known to carry an increased risk of cardiovascular disease, the underlying reasons aren’t clear. Two cross sectional studies from Sweden and the United States report that levels ...

Abstract published as part of the American Society of Hematology (ASH) Annual Meeting Study shows Annamycin effectively targets both Cytarabine (Ara-C) and Venetoclax resistant acute myeloid leukemia ...

School Health LINK provides acute medical care, immunizations, physicals, mental health counseling and more for Rock Island ...

They comprise a group of drugs that inhibit the production of prostaglandins, which serve a variety of purposes in the body ...

The patent filing expands upon data obtained from animal model testing and the istaroxime human clinical trials in acute heart failure (AHF) and early cardiogenic shock (ECS), including the latest ...

Poliovirus Type 1 (WPV1) is the most severe and widespread strain, responsible for the majority of polio outbreaks globally.

It has since been approved in many other regions and countries, including the European Union, the U.S., Saudi Arabia, and Bahrain. Elsewhere, Vertex Pharmaceuticals reported positive phase 3 results ...

The first comprehensive map of the dramatic changes that take place in the blood system over the course of the human lifetime could have implications for the treatment of acute myeloid leukemia and ...

Previous studies predicting cardiovascular disease (CVD) trends have often relied on time series or spatiotemporal ... a relative increase of 5% per year in the in-hospital treatment rate in patients ...